Related references
Note: Only part of the references are listed.Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
Nicolas Gonzalo Nunez et al.
MED (2023)
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Somayeh Vafaei et al.
CANCER CELL INTERNATIONAL (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Immune-related adverse events and the balancing act of immunotherapy COMMENT
Michael Conroy et al.
NATURE COMMUNICATIONS (2022)
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy
Vincent T. Ma et al.
IMMUNOTHERAPY (2022)
Management of Immunotherapy-Related Toxicities, Version 1.2022
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
J. Haanen et al.
ANNALS OF ONCOLOGY (2022)
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life
Thomas U. Schulz et al.
EUROPEAN JOURNAL OF CANCER (2022)
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
Cathrine Lund Lorentzen et al.
LANCET ONCOLOGY (2022)
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Olivier J. van Not et al.
JAMA ONCOLOGY (2022)
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Anne Montfort et al.
CLINICAL CANCER RESEARCH (2021)
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
Jia Luo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors
Anusha S. Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Inflammatory markers in autoimmunity induced by checkpoint inhibitors
Beate Husain et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai et al.
CLINICAL CANCER RESEARCH (2021)
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
Qin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry
Rik J. Verheijden et al.
CLINICAL CANCER RESEARCH (2020)
Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy
Petya Apostolova et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand
James Randall Patrinely et al.
EUROPEAN JOURNAL OF CANCER (2020)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Daniel Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)